Drug facts
MoleculeTriamcinolone
Generics already compete: 30 makers on the market. 70 A-rated products from 27 makers substitute at the counter.
Triamcinolone was first approved by the FDA before 1982 under NDA 011600; the application holder is Extrovis AG. The Orange Book lists NDA 011600 as discontinued.
The latest NADAC for TRIAMCINOLONE 0.025% OINT is $0.07 per gram (as of 10/28/2026).
Holder Extrovis AGApplication NDA 011600Approved before 1982
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Triamcinolone patent listed in the Orange Book Orange Book
- Later patents, other products
- Xipere 04/16/2040; Zilretta 08/04/2031; Triesence 12/17/2029 Orange Book
02Competition
- Generics
- 30 generic makers Orange Book
- First generic approved
- before 1982 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Triamcinolone profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.07 per gramTRIAMCINOLONE 0.025% OINT, mid-priced of 7 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 12/18/2025Class II, Tri-Moxi+¿, Imprimis Njof, LLC FDA enforcement
04Product
- Application holder
- Extrovis AG Orange Book
- Application
- NDA 011600 Orange Book
- First approved
- before 1982 Orange Book
- Dosage forms
- cream; for suspension, extended release; injectable; lotion; ointment; paste
- Routes
- dental, injection, intra-articular, intravitreal
- Other brand names
- Kenalog-10Kenalog-40Kenalog-80Nasacort Allergy 24 HourTridermTriesence
- Status
- NDA 011600 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.